poisar

Stock

Tvardi Therapeutics, Inc. TVRD

$1.83+2.81%

Overview

TVRD market data

Price History

TVRD price chart · 1M
O
1.81
H
1.83
L
1.81
C
1.83
Vol
513.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$1.81
Previous Close
$1.78
Day High
$1.83
Day Low
$1.81
52 Week High
$5.66
52 Week Low
$1.67
7 Day Return
-1.08%
30 Day Return
-25.15%
90 Day Return
-46.02%
1 Year Return
-40.39%
Daily Notional Volume
$938.8
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$46.60
Diluted earnings per share over the trailing twelve months.
Beta
0.36
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-700.1%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.50 – $43.65
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $16.6M · P/B 1.93 · P/S 4.66.

Company News

10 captured
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga · Aug 18, 2026, 9:06 PM
Tvardi Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 14, 2026, 2:36 PM
Tvardi Therapeutics Q2 EPS $(0.69) Beats $(0.70) EstimateBenzinga · Aug 14, 2026, 11:07 AM
8-K filing — Tvardi Therapeutics, Inc. (TVRD)SEC EDGAR · Aug 14, 2026, 11:05 AM
Tvardi Therapeutics To Host KOL Webinar On August 19 To Discuss Current Treatment Landscape In Ulcerative Colitis And Persistent Unmet Needs; Event To Feature New Data From Tvardi And Review Of Phase 1 Healthy Volunteer Results Supporting Potential Of TTI-109 In UCBenzinga · Aug 12, 2026, 12:04 PM
BTIG Maintains Buy on Tvardi Therapeutics, Lowers Price Target to $5Benzinga · Jul 30, 2026, 7:04 PM
Tvardi Therapeutics Selects Ulcerative Colitis As Initial Indication For TTI-109, Says Phase 1 Showed Up To 76% Reduction In Th17 Subsets; Trial Planned For 2027Benzinga · Jul 30, 2026, 11:34 AM
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In SharesBenzinga · Jul 17, 2026, 8:35 PM
Why Is Tvardi Therapeutics Stock Falling Thursday?Benzinga · Jul 9, 2026, 1:10 PM
Tvardi Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 79.35%Benzinga · Jul 8, 2026, 7:45 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock